Increased Online Selling to significantly contribute to the US Polycystic Ovarian Syndrome Treatment Market further

The continuous declining cost of branded medications will ultimately augment the adoption of the US polycystic ovarian syndrome drugs. Furthermore, the market is driven by intensifying expenditure from several funding agencies and government. Non-approval of drugs by agencies including FDA and EMA is significantly contributing the growth, eventually providing notable avenues to the manufacturers operating in this region. In addition, the increasing number of patients diagnosed with diabetes are constantly rising in the US. This is indirectly generating outstanding demand for polycystic ovarian syndrome treatment in the region.

Factors driving the market growth

  • Insulin sensitizing agents

Dominance of insulin sensitizing agents is ominously attributing to the regional growth. Other types of drug class segments are aromatase inhibitors &SERMs, anti-depressants, oral contraceptives, ornithine decarboxylase inhibitors, and, diuretics. Insulin sensitizing gents being the market leader, is anticipated to cross revenues worth $100 million and will cover over 30% of the total market shares.

The industry for insulin sensitizing agents is profitably expanding in the US owing to rising number of patients with polycystic ovarian syndrome. According to the estimations, around 70% of these patients are overweight and susceptible to be diagnosed with type 2 diabetes. This is further amplifying the industry demand for polycystic ovarian syndrome treatment in the US.

Projections assume that over US$ 66 million of oral contraceptive drugs were consumed in the year 2016. The market for contraceptives is expanding at the significant CAGR of close to 5.3% and will possibly contribute around one-third shares.

  • Advanced Treatment Process and Increased Online Selling Will Propel the Industry

Rising inclination of people towards more advanced treatment procedures for several ailments is boosting the market demand. This is mainly owing to rising healthcare spending in several countries in the US. Amplified research and development initiatives in order to introduce novel drugs in the market will boost the regional demand in the coming times. These drugs would be generally for unconventional treatment for hirsutism, obesity, and insulin sensitivity. Amplified commercial distribution of medicines by top market players in this region mainly through online portals and wholesale pharmacies will positively affect the market growth. Especially, the market for online is displaying high demand, thus, driving the overall market for polycystic ovary syndrome treatment. This owes to the online selling of the drugs without the prescription.

A sample of this report is available upon request @

Market projections for polycystic ovary syndrome treatment (2016-2024)

The demand for PCOS treatment will grow steadily across the US. According to a report, currently, the market value is at US$ 230 million. It is further predictable to rise at the moderate value CAGR of 3.9% and will probably reach close to US$ 313 million by the end of the projected period (2016-2024).

By the end of 2024, above 47% of US polycystic ovary syndrome treatment market shares is expected to be contributed by drug sales via hospital pharmacies. According to the estimations, nearly US$ 150 Mn worth of PCOS drugs is anticipated to be sold through these pharmacies.

PCOS drug sales through e-commerce platforms, on the other hand, are likely to display a value CAGR of 4.6%. It is comparatively greater than hospital pharmacies and other distribution channels including fertility clinics, drug stores, and over-the-top counters.

Be the first to comment

Leave a Reply

Your email address will not be published.